NASDAQ$ZLAB
Zai Lab Limited-ADR · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Reported strong revenue growth and pipeline advancements.
Zai Lab reported a strong third quarter with a 47% year-over-year increase in net product revenue, driven by VYVGART sales. The company also saw positive results from the China bridging study of KarXT and expects regulatory submissions in early 2025. Additionally, Zai Lab anticipates three product launches in mainland China by the end of 2024.
- Net product revenue increased by 47% year-over-year, reaching $101.8 million.
- VYVGART sales were a primary driver of revenue growth.
- Positive results from the China bridging study of KarXT for schizophrenia were achieved, with regulatory submission expected in early 2025.
- Global Phase 1 data of ZL-1310 suggests best-in-class potential in extensive-stage SCLC.
Headline financials
Revenue & EPS history
Zai Lab · Revenue · Quarterly
$102M
Revenue by segment
Zai Lab · $52M total across 3 segments · Q3 2023
- ZEJULA$41.6M+6.1%80.0%
- NUZYRA$5.5M+266.7%10.6%
- VYVGART franchise$4.9M—9.4%
Forward guidance
Zai Lab anticipates continued commercial launches and regulatory submissions, supported by ongoing clinical development programs.
Tailwinds
- Expected commercial launches of XACDURO, VYVGART Hytrulo, and AUGTYRO in China by the end of 2024.
- Potential NMPA submission for KarXT in schizophrenia in early 2025.
- Potential NMPA submission for TTFields in second-line+ NSCLC.
- Potential BLA submission for Tisotumab Vedotin in recurrent or metastatic cervical cancer.
- Potential supplementary NDA submission for Repotrectinib in NTRK+ solid tumors.
Headwinds
- Risks related to commercializing approved products.
- Risks associated with obtaining funding for operations and business initiatives.
- Uncertainties in clinical and pre-clinical development of product candidates.
- Potential delays or adverse decisions by regulatory authorities.
- Risks related to doing business in China.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
-0.1%
Avg return
Earnings day
+0.3%
Avg return
5 days after
-0.5%
Avg return
30 days after
45%
13 / 29 earnings
Positive
+26.0%
Q1 2024
Best reaction
-11.2%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.9% | -7.0% | -20.9% | |
| Q4 2025 | +1.7% | -8.6% | -7.2% | |
| Q3 2025 | -6.4% | -11.3% | -21.4% | |
| Q1 2025 | +2.5% | +0.9% | +34.4% | |
| Q4 2024 | -2.0% | -3.1% | +6.3% | |
| Q3 2024 | -3.7% | -13.0% | -14.1% | |
| Q2 2024 | -5.6% | -7.8% | +11.3% | |
| Q1 2024 | +26.0% | +29.0% | +19.9% | |
| Q4 2023 | -0.9% | +0.5% | -23.7% | |
| Q3 2023 | +7.4% | +0.9% | -1.5% | |
| Q2 2023 | -11.2% | -5.4% | +3.5% | |
| Q1 2023 | +1.4% | -9.3% | -24.2% | |
| Q4 2022 | -0.6% | +7.3% | -10.5% | |
| Q3 2022 | +1.9% | +23.9% | +18.7% | |
| Q2 2022 | -5.0% | -6.2% | -8.0% | |
| Q1 2022 | -2.1% | +30.0% | +5.6% | |
| Q4 2021 | -4.0% | -26.0% | -19.6% | |
| Q3 2021 | +0.7% | -2.3% | -22.3% | |
| Q2 2021 | +0.6% | +0.9% | +0.4% | |
| Q1 2021 | -5.1% | -3.3% | +8.3% | |
| Q4 2020 | +0.3% | -7.0% | -9.6% | |
| Q4 2019 | -1.4% | -2.7% | +17.0% | |
| Q1 2020 | -8.7% | +3.1% | +18.3% | |
| Q2 2019 | +4.3% | +4.1% | -4.0% | |
| Q1 2019 | +3.7% | +6.7% | -9.7% | |
| Q4 2018 | +10.4% | +10.4% | +1.6% | |
| Q3 2018 | +6.7% | +13.6% | +13.1% | |
| Q4 2017 | -5.3% | -8.8% | +22.8% | |
| Q3 2017 | -2.2% | -0.6% | +0.3% | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro